DE69920681T2 - Humaner k+ ionenkanal und therapeutische verwendungen davon - Google Patents

Humaner k+ ionenkanal und therapeutische verwendungen davon Download PDF

Info

Publication number
DE69920681T2
DE69920681T2 DE69920681T DE69920681T DE69920681T2 DE 69920681 T2 DE69920681 T2 DE 69920681T2 DE 69920681 T DE69920681 T DE 69920681T DE 69920681 T DE69920681 T DE 69920681T DE 69920681 T2 DE69920681 T2 DE 69920681T2
Authority
DE
Germany
Prior art keywords
nucleic acid
acid molecule
cells
poly
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920681T
Other languages
German (de)
English (en)
Other versions
DE69920681D1 (de
Inventor
Luis Angel Pardo-Fernandez
Walter STÜHMER
Synnöve BECKH
Andrea BRÜGGEMANN
Donato Neurobiology Dept. Boston DEL CAMINO FERNANDEZ-MIRANDA
Araceli Sanchez Perez
Rüdiger WESELOH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of DE69920681D1 publication Critical patent/DE69920681D1/de
Publication of DE69920681T2 publication Critical patent/DE69920681T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69920681T 1998-04-21 1999-04-21 Humaner k+ ionenkanal und therapeutische verwendungen davon Expired - Lifetime DE69920681T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98107268 1998-04-21
EP98107268 1998-04-21
PCT/EP1999/002695 WO1999054463A2 (en) 1998-04-21 1999-04-21 Human k+ ion channel and therapeutic applications thereof

Publications (2)

Publication Number Publication Date
DE69920681D1 DE69920681D1 (de) 2004-11-04
DE69920681T2 true DE69920681T2 (de) 2005-09-08

Family

ID=8231794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920681T Expired - Lifetime DE69920681T2 (de) 1998-04-21 1999-04-21 Humaner k+ ionenkanal und therapeutische verwendungen davon

Country Status (10)

Country Link
US (7) US6638736B1 (enExample)
EP (1) EP1073738B1 (enExample)
JP (2) JP2002512029A (enExample)
AT (1) ATE278017T1 (enExample)
CA (1) CA2323571A1 (enExample)
DE (1) DE69920681T2 (enExample)
DK (1) DK1073738T3 (enExample)
ES (1) ES2230852T3 (enExample)
PT (1) PT1073738E (enExample)
WO (1) WO1999054463A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230852T3 (es) * 1998-04-21 2005-05-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Canales ionicos de k+humanos y aplicaciones terapeuticas de los mismos.
DE10025620A1 (de) * 2000-05-24 2001-12-06 Forschungsgesellschaft Genion Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten
DE10224534A1 (de) 2002-05-31 2003-12-11 Juergen Dolderer Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung
MX2007003865A (es) * 2004-10-01 2009-06-17 Ct Investig Y Estudios Del Ipn Métodos para el diagnóstico temprano de infecciones virales y enfermedades inflamatorias o de la predisposición de un individuo a desórdenes proliferativos o hiperplasia.
ATE497508T1 (de) 2004-10-01 2011-02-15 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
AU2013201604B2 (en) * 2007-04-13 2014-08-14 Southern Research Institute Anti-angiogenic agents and methods of use
ES2334084B1 (es) * 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
TWI570415B (zh) * 2015-10-02 2017-02-11 A spring probe having an outer sleeve and a probe device having the spring probe
EP3195727A1 (en) 2016-01-22 2017-07-26 Forschungsinstitut Fur Biologischen Landbau (FiBL) Duddingtonia flagrans strain and feed additive formulation for biological pest control

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
WO1992011034A1 (en) 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
WO1998000168A1 (en) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
US6610827B1 (en) * 1997-10-29 2003-08-26 Elan Pharmaceuticals, Inc. Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
ES2230852T3 (es) * 1998-04-21 2005-05-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Canales ionicos de k+humanos y aplicaciones terapeuticas de los mismos.

Also Published As

Publication number Publication date
EP1073738B1 (en) 2004-09-29
US20030087377A1 (en) 2003-05-08
DK1073738T3 (da) 2005-01-24
US20030092120A1 (en) 2003-05-15
US20080020406A1 (en) 2008-01-24
US7364730B2 (en) 2008-04-29
EP1073738A2 (en) 2001-02-07
US6638736B1 (en) 2003-10-28
US7364845B2 (en) 2008-04-29
US7129207B2 (en) 2006-10-31
US20100021467A1 (en) 2010-01-28
JP2009235091A (ja) 2009-10-15
ES2230852T3 (es) 2005-05-01
JP2002512029A (ja) 2002-04-23
CA2323571A1 (en) 1999-10-28
ATE278017T1 (de) 2004-10-15
US7314914B2 (en) 2008-01-01
WO1999054463A2 (en) 1999-10-28
WO1999054463A3 (en) 2000-04-20
US20030077735A1 (en) 2003-04-24
DE69920681D1 (de) 2004-11-04
US20030087378A1 (en) 2003-05-08
PT1073738E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
DE69631540T2 (de) Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs-suszeptilitaetsgens brca2 und dessen anwendungen
DE69532767T2 (de) Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III
DE69635455T2 (de) Dna kodierend für glutaminsäure-gesteuerte chloridkanäle
DE69733933T2 (de) Neue Liganden des Neuropeptid Rezeptors HFGAN72
DE69535634T2 (de) Modulatoren der funktion des fas/ap01 rezeptors
US20100021467A1 (en) Method of detecting a cancer cell by aberrant expression of a human k+ ion channel
DE69333019T2 (de) Delta opioidrezeptor-gene
DE69533796T2 (de) Für die glutamatabhängigen chloridkanäle kodierende dna
DE69535590T2 (de) Für den bradykinin-b1-rezeptor kodierende dna
DE69427921T2 (de) Epsilon opioid rezeptor und dessen verwendungen
DE69525366T2 (de) Die verwendung von bmp-protein-rezeptor komplexen für das screening von substanzen aus dem knochenmetabolismus und zellen die mit einem typ i- und typ ii-bmp-rezeptor co-transfiziertsind
US7122325B2 (en) Method of modulating tetrotodoxin-resistant sodium channel
DE69931345T2 (de) Gen, welches für neues transmembranprotein kodiert
DE10004815B4 (de) Menschliche intestinale Natriumphosphat-Kotransporter
DE69534753T2 (de) Nierenpolycystose-gen
EP0805204B1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
DE60132571T2 (de) Für den menschlichen vanilloid-rezeptor vr3 kodierende dns
DE10246329B4 (de) Duftstoffrezeptoren
DE69836546T2 (de) Menschliches, durch kalzium aktivierbares kaliumkanalpolypeptid aus leukozyten
EP1102847B1 (de) Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika
DE69434333T2 (de) Methoden unter verwendung von eaa3 oder eaa4 rezeptoren
DE69334043T2 (de) Screening-Verfahren für calciumrezeptoraktive Moleküle
DE19963612B4 (de) Neue spannungsabhängige Kaliumkanäle aus der Kv4-Familie sowie deren Verwendung zur Entwicklung von Therapeutika
DE60120420T2 (de) Mfq-111, ein menschliches gtpase-ähnlichers protein
EP1499639A1 (de) Neue nukleinsäuresequenzen und proteine von tumoren und neoplasien der schilddrüse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition